Pathos AI Secures $365 Million in Series D Funding to Accelerate AI-Powered Cancer Drug Development

Pathos AI, a clinical-stage biotech company leveraging artificial intelligence to revolutionize cancer treatment, has announced the successful close of a $365 million Series D funding round. The funding will support the development of AI-driven oncology therapeutics, including solid tumor drug candidates from Novo Nordisk and Prelude Therapeutics.

The latest investment round values Pathos at an estimated $1.6 billion, reflecting strong investor confidence in the company’s proprietary PathOS Platform, which integrates multimodal data—including molecular, clinical, and imaging datasets—to optimize oncology drug development.

Focus on Clinical-Stage Pipeline: Pocenbrodib and P-500

A key focus of the Series D funding will be the continued advancement of pocenbrodib, a CBP/p300 inhibitor licensed from Novo Nordisk in 2023. Originally developed by Forma Therapeutics, pocenbrodib is currently undergoing Phase 1b/2a clinical trials for metastatic castration-resistant prostate cancer (mCRPC). The trials are evaluating the drug both as a monotherapy and in combination with Zytiga, Lynparza, and Pluvicto.

Pathos believes pocenbrodib holds promise beyond prostate cancer, with potential applications across a broad range of solid tumor types.

In addition, Pathos plans to initiate clinical development of P-500, a brain-penetrant PRMT5 inhibitor licensed from Prelude Therapeutics, later in 2024. Prelude previously evaluated P-500 in a Phase 1 trial involving patients with uveal melanoma and high-grade gliomas.

Leveraging AI to Revolutionize Oncology

Pathos’ AI-powered PathOS Platform is at the core of its strategy, enabling the identification of predictive biomarkers and the design of precision-targeted clinical trials. The company aims to use the new capital to accelerate platform enhancements, improve patient stratification, and increase the speed and success rate of oncology drug development.

“Our mission at Pathos is to transform oncology drug development by harnessing the full potential of multimodal data and artificial intelligence,” said Iker Huerga, the newly appointed CEO of Pathos AI. Huerga previously served as Chief Data Scientist for Oncology R&D at AstraZeneca.

Continued Growth and Strategic Acquisitions

The Series D round included participation from both existing backers and new investors. This follows a $62 million Series C round led by New Enterprise Associates (NEA) just seven months ago.

In a strategic move last December, Pathos acquired Rain Oncology, adding the Phase 3-stage MDM2 inhibitor milademetan to its pipeline. However, the company has yet to comment on future plans for the asset, which previously failed in liposarcoma trials.

About Pathos AI

Pathos AI is a Boston-based biotechnology company applying advanced artificial intelligence and multimodal data analytics to accelerate the discovery and development of next-generation oncology therapeutics. Through its proprietary PathOS Platform, the company is redefining how cancer treatments are identified, developed, and delivered.